EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Lisa Licitra(University of Milan), Robert L. Ferris(University of Pittsburgh), С. И. Кутукова(City Clinical Oncology Center), Jérôme Fayette(Université Claude Bernard Lyon 1), Lyubov Zholudeva, Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Ihor Vynnychenko(Sumy State University), Nassim Morsli(Boehringer Ingelheim (France)), Jagdish Shetty(AstraZeneca (United States)), Mikhail Dvorkin(Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"), Helen Mann(AstraZeneca (United Kingdom)), Bhumsuk Keam(Seoul National University Hospital), Robert I. Haddad(Broad Institute), Amaury Daste(Centre Hospitalier Universitaire de Bordeaux), Paul Clement(KU Leuven), Javier Daroqui Caballero(Hospital Universitari i Politècnic La Fe), Caroline Even(Institut Gustave Roussy), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Cédrik Lafond(Centre Jean Bernard), Makoto Tahara(National Cancer Center Hospital East)
Cited by 39
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k